Drawing for UNLOCK THE VALUE OF YOUR CLINICAL DATA

USPTO serial 97056027

UNLOCK THE VALUE OF YOUR CLINICAL DATA

Reviewed by CopyMark Law Group

Reg. 8111300Status 700Registered
Filing date
Status date
Registration date
Jan 20, 2026
Examiner
REGAN,JOHN B
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with UNLOCK THE VALUE OF YOUR CLINICAL DATA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Matthew Saunders

Matthew Saunders SAUNDERS & SILVERSTEIN LLP14 CEDAR STREET SUITE 224AMESBURY, MA 01913United States

Goods and services

ClassDescriptionStatusFirst use
035consulting in the fields of healthcare operations management and hospital operations management; business services provided to the healthcare industry, namely, the collection, reporting, and analysis of healthcare data for business purposes; business services provided to the healthcare industry, namely, core measure abstraction services in the nature of extracting and summarizing information from medical records, and registry abstraction services in the nature of extracting and summarizing information from medical records; statistical analysis for business purposes, namely, review of hospital mortality statistics; providing independent reviews of other businesses for commercial purposes, namely, peer review of medical services and peer review of complaints by recipients regarding the quality of medical care received; statistical analysis and reporting of data for business purpose, namely, for use in infection control and prevention services, in patient readmission reduction services, and in quality surveillance services, namely, collection, reporting, and analysis of healthcare quality data for business purposes; business-risk assessment services provided to the healthcare industry, namely, assessment and prediction of patient readmission riskACTIVE—
042Software as a service (SAAS) services featuring software for use in healthcare data abstraction; Software as a service (SAAS) services featuring software for use in the collection, compilation, abstraction, analysis, and reporting of healthcare data; Software as a service (SAAS) services featuring software for use in time tracking and workflow management of healthcare personnel; Software as a service (SAAS) services featuring software for use by hospitals and health care providers in the collection, compilation, and analysis of healthcare quality performance data and key performance metrics; Software as a service (SAAS) services featuring software enabling hospitals and health care providers to submit healthcare quality performance data to third parties for business purposesACTIVE—
044medical consulting services in the field of disease infection control; medical consulting services in the field of infection screening, control, and prevention; medical consulting services to health care providers in the field of the detection and prevention of healthcare-associated infections; medical consultancy, namely, review of hospital mortality causesACTIVE—
045Regulatory compliance consulting in the field of healthcare; Providing information and advice regarding regulatory compliance in the field of healthcareACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 20, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 20, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 29, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Dec 29, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Dec 10, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 10, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 8, 2025ALIEASSIGNED TO LIE—
Nov 21, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 18, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 18, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 18, 2025CNRTSU - NON-FINAL ACTION - WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 26, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 24, 2025IUAFUSE AMENDMENT FILED—
Oct 24, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Sep 27, 2025EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 26, 2025EX5GSOU EXTENSION 5 GRANTED—
Sep 26, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
May 8, 2025EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 7, 2025EXT5SOU EXTENSION 5 FILED—
Apr 23, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 23, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 23, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Oct 31, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 31, 2024EX4GSOU EXTENSION 4 GRANTED—
Oct 31, 2024EXT4SOU EXTENSION 4 FILED—
Oct 31, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 9, 2024EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 8, 2024EX3GSOU EXTENSION 3 GRANTED—
May 8, 2024EXT3SOU EXTENSION 3 FILED—
May 8, 2024EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 4, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Nov 2, 2023EX2GSOU EXTENSION 2 GRANTED—
Nov 2, 2023EXT2SOU EXTENSION 2 FILED—
Nov 2, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 29, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 27, 2023EX1GSOU EXTENSION 1 GRANTED—
Apr 27, 2023EXT1SOU EXTENSION 1 FILED—
Apr 27, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 8, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 13, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 13, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 24, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 5, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 11, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Jul 11, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jul 11, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Jul 11, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 5, 2022DOCKASSIGNED TO EXAMINER—
Oct 29, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 5, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance